Optimising R&D
Challenges
Currently R&D organisations are under significant pressure as their productivity remains unsatisfactory despite massive increases in R&D spending and significant efforts to improve operational excellence. Due to the poor R&D results over the last couple of years, and given the fact that 25% of big pharma sales go off patent by 2012, immediate actions are required and the current business models have to be re-invented.
The R&D practice of the future will have to cope with:
- Increasing development and patient cost
- Safety as a key factor for confidence and trust
- Efficient pipeline management to improve output
- Appropriate intellectual property management to facilitate innovation
- Evolving stakeholder issues
- Multiple partnerships within the complete R&D value chain
Deloitte services offering
Deloitte can help life sciences companies:
- Improve R&D governance
- Focus on ways to accelerate the R&D cycle
- Optimise & manage their portfolio of intellectual property
- Streamline the different R&D process flows
- Improve safety management, risk management and diminish regulatory exposure
Material on this website is © 2012 Deloitte Global Services Limited, or a member firm of Deloitte Touche Tohmatsu Limited, or one of their affiliates. See Legal for copyright and other legal information.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.